NFX appoints Idiopathic Lung Fibrosis expert to advisory board
, the AIM listed pharmaceutical company developing cocrystal technology to unlock therapeutic potential of approved small molecule drugs, on Friday appointed Dr Muhunthan Thillai to its Scientific Advisory Board.
Dr. Muhunthan Thillai is the Lead Clinician for the Cambridge Interstitial Lung Disease Unit, with a specific interest in sarcoidosis and Idiopathic Lung Fibrosis (IPF).
He was granted options for up to 6 million shares in Nuformix subject to milestone achievements lock-in agreements as part of the appointment.
Dr Muhunthan Thillai, commenting on his appointment said: “Current therapies lack meaningful efficacy and their side effects can be so severe that some patients elect to stop treatment. Nuformix's approach offers the potential to move rapidly into clinic and allows us to explore other unmet needs in interstitial lung disease together."
Shares in Nuformix were trading 12% higher by midday following the appointment
Dr Dan Gooding, Chief Executive Officer, Nuformix commented: “Muhunthan has a complete understanding of IPF patients, from those newly diagnosed to those receiving lung transplants at end stage and runs the UK's second largest IPF patient clinic at Royal Papworth.”
He said that Muhunthan’s in-depth understanding of patients' needs and the short-comings of existing therapies will enable Nuformix to identify how its NXP002 programme can offer greatest benefit for patients.
He added: “Muhunthan has already contributed to numerous IPF clinical studies and is currently developing new technologies and novel imaging biomarkers that improve assessment of disease progression. On top of this, he is highly respected by his peers and well connected with the major academic and pharmaceutical players in IPF.”
Dr. Gooding emphasized that Muhunthan provides “invaluable experience” in the design and execution of future Nuformix clinical studies in IPF for the company’s NXP002 programme.
Dr Andy Richards CBE Chair of the Nuformix Scientific Advisory Board said in a statement: "It is very encouraging that the data generated and the progress made to date for NXP002 warrant building up clinical expertise in IPF for further development. Muhunthan, brings deep knowledge of this important disease and his insight into biomarkers of IPF progression will be especially invaluable for clinical trial design.”
“His dynamism coupled to his proximity to the Nuformix team in his role at at Royal Papworth will facilitate real impact on NXP002 development"
Dr. Thillai began training as a junior doctor in London and Oxford, gaining Membership of the Royal College of Physicians. He has been awarded a number of clinical and research prizes from societies including the Eastern Thoracic Society, Imperial College London and the National Heart and Lung Institute.
He is also the editor of five books, has written numerous book chapters and research papers in sarcoidosis and has given presentations at several international scientific meetings.
Follow News & Updates from Nuformix here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.